Table 3.

Eligible studies evaluating prognostication, in chronological order

Ref.	No. of patients	Cancer type	No. of lesions	Spectrum of tumor sizes (mm)a	Effect on prognostication?
[35]	145	NSCLC	NS	Median 30 (range 10–110)	Not improved
[36]	52	Esophageal	NS	NS	Not improved
[37]	50	Esophageal	NS	39.9 ± 36.1 mL	Not improved
[38]	191	NSCLC	NS	Median 23 (range 10–36)	Not improved
[39]	19	HNC	19	15.2 ± 5.0	Improved
[40]	19	HNC	19	15 ± 5	Improved for subgroup

NSCLC non-small cell lung cancer, mLN lymph node metastases, HNC head and neck cancer, NS not specified

^aSizes are presented as mean ± SD, unless stated otherwise